Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.19+0.00 (+2.01%)
Close on Nov 17, 2026Market cap $8.34MP/E –Yield –
Vistagen Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Vistagen Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$69.66M. For fiscal 2026 it was -$72.13M. The highest annual figure on record is -$5.03M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$72.13M | – |
| FY2025 | Mar 31, 2025 | -$55.97M | – |
| FY2024 | Mar 31, 2024 | -$33.02M | – |
| FY2023 | Mar 31, 2023 | -$59.27M | – |
| FY2022 | Mar 31, 2022 | -$47.78M | – |
| FY2021 | Mar 31, 2021 | -$17.93M | – |
| FY2020 | Mar 31, 2020 | -$20.80M | – |
| FY2019 | Mar 31, 2019 | -$24.56M | – |
| FY2018 | Mar 31, 2018 | -$14.20M | – |
| FY2017 | Mar 31, 2017 | -$10.25M | – |
| FY2016 | Mar 31, 2016 | -$17.85M | – |
| FY2015 | Mar 31, 2015 | -$6.78M | – |
| FY2014 | Mar 31, 2014 | -$5.03M | – |
| FY2013 | Mar 31, 2013 | -$6.79M | – |
| FY2012 | Mar 31, 2012 | -$9.04M | – |
| FY2011 | Mar 31, 2011 | -$6.56M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$13.35M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$16.72M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$19.55M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$20.05M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$15.80M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$14.50M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$15.12M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$14.23M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$12.13M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$11.36M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$7.88M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$6.78M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$7.00M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$12.24M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$9.77M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$17.49M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$19.77M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$16.69M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$10.54M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$12.80M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$7.75M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$6.22M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$5.30M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$3.29M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$3.12M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$3.26M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$5.96M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$5.35M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$6.22M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$5.72M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$7.19M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$7.43M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$4.21M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$4.08M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$2.87M | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$4.99M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$2.26M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -$2.55M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -$2.64M | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | -$3.10M | – |
See a number that looks wrong?